Tipranavir

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Virustatic. Inhibitor of HIV protease. Non-peptide protease inhibitor.

Pharmacodynamics (Effect)This section has been translated automatically.

Inhibition of the HIV-1 aspartyl protease and suppression of the maturation of virus particles in the host cell

IndicationThis section has been translated automatically.

In combination with low-dose ritonavir for antiretroviral combination therapy of HIV-1 infection in multi-treated adult patients with viruses resistant to multiple protease inhibitors.

Dosage and method of useThis section has been translated automatically.

2 times/day 500 mg p.o. each in combination with ritonavir 100 mg p.o.

Undesirable effectsThis section has been translated automatically.

Very often: diarrhoea, nausea. Also: headaches, stomach aches, skin changes. Liver toxicity (increased transaminases).

PreparationsThis section has been translated automatically.

Aptivus

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer